Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications
Laura E. Targownik, Eric I. Benchimol, Çharles N. Bernstein, et al.
Journal of Crohn s and Colitis (2020) Vol. 14, Iss. 10, pp. 1354-1363
Closed Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
Tim Raine, Stefanos Bonovas, Johan Burisch, et al.
Journal of Crohn s and Colitis (2021) Vol. 16, Iss. 1, pp. 2-17
Closed Access | Times Cited: 608
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
Bruce E. Sands, Peter M. Irving, Timothy Hoops, et al.
The Lancet (2022) Vol. 399, Iss. 10342, pp. 2200-2211
Closed Access | Times Cited: 179
Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User’s Guide for Adult and Pediatric Gastroenterologists
Manasi Agrawal, Elizabeth Spencer, Jean‐Frédéric Colombel, et al.
Gastroenterology (2021) Vol. 161, Iss. 1, pp. 47-65
Open Access | Times Cited: 156
ECCO Guidelines on Inflammatory Bowel Disease and Malignancies
Hannah Gordon, Livia Biancone, Gionata Fiorino, et al.
Journal of Crohn s and Colitis (2022) Vol. 17, Iss. 6, pp. 827-854
Open Access | Times Cited: 135
ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment
Hannah Gordon, Silvia Minozzi, Uri Kopylov, et al.
Journal of Crohn s and Colitis (2024)
Open Access | Times Cited: 49
Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease
Salma Sultan, Mohammed El‐Mowafy, Abdelaziz Elgaml, et al.
Frontiers in Physiology (2021) Vol. 12
Open Access | Times Cited: 84
AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease
Siddharth Singh, Deborah D. Proctor, Frank I. Scott, et al.
Gastroenterology (2021) Vol. 160, Iss. 7, pp. 2512-2556.e9
Open Access | Times Cited: 74
Shared decision-making in the management of patients with inflammatory bowel disease
Kai Song, Dong Wu
World Journal of Gastroenterology (2022) Vol. 28, Iss. 26, pp. 3092-3100
Open Access | Times Cited: 60
Nanotechnology for inflammatory bowel disease management: Detection, imaging and treatment
Mahmood Barani, Abbas Rahdar, Saman Sargazi, et al.
Sensing and Bio-Sensing Research (2021) Vol. 32, pp. 100417-100417
Open Access | Times Cited: 56
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy
Giuseppe Privitera, Daniela Pugliese, S. Onali, et al.
Autoimmunity Reviews (2021) Vol. 20, Iss. 6, pp. 102832-102832
Closed Access | Times Cited: 54
Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
Soo‐Young Na, Chang Hwan Choi, Eun Mi Song, et al.
Intestinal Research (2022) Vol. 21, Iss. 1, pp. 61-87
Open Access | Times Cited: 36
Analysis of the risk of oncological adverse events associated with infliximab in combination with azathioprine compared to monotherapy: insights from the FAERS database
Qian Qiao, Jiachen Sun, Ya Zheng, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Pectin
Huizi Tan, Hong Yao, Shaoping Nie
Elsevier eBooks (2025), pp. 39-64
Closed Access
Characteristics of immune cell infiltration and associated diagnostic biomarkers in ulcerative colitis: results from bioinformatics analysis
Guohui Xue, Lin Hua, Nanjin Zhou, et al.
Bioengineered (2020) Vol. 12, Iss. 1, pp. 252-265
Open Access | Times Cited: 39
Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease
J Schultheiss, Remi Mahmoud, J Louwers, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 10, pp. 1298-1308
Open Access | Times Cited: 39
Prevention and Alleviation of Dextran Sulfate Sodium Salt-Induced Inflammatory Bowel Disease in Mice With Bacillus subtilis-Fermented Milk via Inhibition of the Inflammatory Responses and Regulation of the Intestinal Flora
Xuan Zhang, Yanjun Tong, Xiaomei Lyu, et al.
Frontiers in Microbiology (2021) Vol. 11
Open Access | Times Cited: 37
Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor α Antagonists in Inflammatory Bowel Diseases
David Cheng, Bharati Kochar, Tianxi Cai, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 20, Iss. 10, pp. 2366-2372.e6
Open Access | Times Cited: 25
Increasing Prevalence and Stable Incidence Rates of Inflammatory Bowel Disease Among First Nations: Population-Based Evidence From a Western Canadian Province
Juan Nicolas Peña-Sánchez, Jessica Amankwah Osei, José Diego Marques Santos, et al.
Inflammatory Bowel Diseases (2021) Vol. 28, Iss. 4, pp. 514-522
Open Access | Times Cited: 31
Oral administration of pasteurized probiotic fermented milk alleviates dextran sulfate sodium-induced inflammatory bowel disease in rats
Cuijiao Feng, Weiqin Zhang, Tao Zhang, et al.
Journal of Functional Foods (2022) Vol. 94, pp. 105140-105140
Open Access | Times Cited: 19
Durability of the First Biologic in Children and Adults With Ulcerative Colitis: A Nationwide Study from the epi-IIRN
Ohad Atia, C Friss, Gili Focht, et al.
Inflammatory Bowel Diseases (2024)
Closed Access | Times Cited: 3
Twenty‐five years of biologicals in IBD: What´s all the hype about?
Klaus Herrlinger, Eduard F. Stange
Journal of Internal Medicine (2021) Vol. 290, Iss. 4, pp. 806-825
Open Access | Times Cited: 23
Durability of the First Biologic in Patients with Crohn’s Disease: A Nationwide Study from the epi-IIRN
Ohad Atia, C Friss, Gili Focht, et al.
Journal of Crohn s and Colitis (2023) Vol. 18, Iss. 1, pp. 38-46
Closed Access | Times Cited: 8
Withdrawal of Immunomodulators or TNF Antagonists in Patients With Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis
David J. Katibian, Virginia Solitano, D. Brent Polk, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 22, Iss. 1, pp. 22-33.e6
Closed Access | Times Cited: 7
Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches
Catherine O’Reilly, Susan Mills, Mary C. Rea, et al.
Microbiome Research Reports (2023) Vol. 2, Iss. 4
Open Access | Times Cited: 7
Infliximab for medical induction of remission in Crohn's disease
Morris Gordon, Vassiliki Sinopoulou, Anthony K Akobeng, et al.
Cochrane library (2023) Vol. 2023, Iss. 12
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top